Start of Phase 1 trial of NS-229
First written in FY2021-Q2. 9 of 12 entries say "Restated". Latest entry: FY2025-H1.
No other company in this theme has enough history to compare yet.
- FY2025-H1AdvancedAnnual report
「The global Phase 2 trial of NS-229, a treatment for eosinophilic granulomatosis with polyangiitis, has been underway since June 2024.」
NS-229 progressed from the preparation stage for the global Phase 2 trial to the trial stage in June 2024. - FY2024-Q3RestatedAnnual report
「Preparations are underway for the global Phase 2 trial of NS-229, a treatment for eosinophilic granulomatosis with polyangiitis.」
The preparations for the global Phase 2 trial of NS-229 for eosinophilic granulomatosis with polyangiitis have been reiterated. - FY2024-Q2RestatedAnnual report
「Preparations are underway for the global Phase 2 trial of NS-229, a treatment for eosinophilic granulomatosis with polyangiitis.」
The preparations for the global Phase 2 trial of NS-229 for eosinophilic granulomatosis with polyangiitis have been reiterated. - FY2024-Q1ReframedAnnual report
「Preparations are underway for the global Phase 2 trial of NS-229, a treatment for eosinophilic granulomatosis with polyangiitis.」
For NS-229, the description has been revised from the start of the Phase 1 trial of a JAK1 inhibitor to preparations for a global Phase 2 trial for eosinophilic granulomatosis with polyangiitis. - FY2023RestatedAnnual report
「The Phase 1 trial of the JAK1 inhibitor NS-229, which began in October 2020, is ongoing.」
The Phase 1 trial of NS-229, which began in October 2020, is ongoing. - FY2023-Q2RestatedAnnual report
「The Phase 1 trial of the JAK1 inhibitor NS-229, which began in October 2020, is ongoing.」
The Phase 1 trial of NS-229, which began in October 2020, is ongoing. - FY2022-Q3RestatedAnnual report
「The Phase 1 trial of the JAK1 inhibitor NS-229 began in October 2020.」
The status of the Phase 1 trial of NS-229, which began in October 2020, has been reiterated. - FY2022-Q2RestatedAnnual report
「The Phase 1 trial of the JAK1 inhibitor NS-229 began in October 2020.」
The status of the Phase 1 trial of NS-229, which began in October 2020, has been reiterated. - FY2022-Q1RestatedAnnual report
「The Phase 1 trial of the JAK1 inhibitor NS-229 began in October 2020.」
The status of the Phase 1 trial of NS-229, which began in October 2020, has been reiterated. - FY2021RestatedAnnual report
「The Phase 1 trial of the JAK1 inhibitor NS-229 began in October 2020.」
The Phase 1 trial of NS-229, which began in October 2020, has been reiterated. - FY2021-Q3RestatedAnnual report
「The Phase 1 trial of the JAK1 inhibitor NS-229 began in October 2020.」
The status of the Phase 1 trial of NS-229, which began in October 2020, has been reiterated. - FY2021-Q2First statedAnnual report
「The Phase 1 trial of the JAK1 inhibitor NS-229 began in October 2020.」
The start of the Phase 1 trial of the JAK1 inhibitor NS-229 in October 2020 was disclosed for the first time.